Publication | Closed Access

Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations

CardiomyopathyHeart FailureCardiovascular DiseasePositive Inotropic EffectsMedicinePhysiologyCardiovascular PharmacologyPharmacotherapyPhosphodiesterase Iii InhibitorsCardiovascular FunctionPharmacologyCardiology